SXTPW · 60 Degrees Pharmaceuticals, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated these conditions and its plans to mitigate them and concluded that, collectively, such plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern for at least one year after the date these consolidated condensed financial statements are issued.”View the 10-Q filed Aug 14, 2026
Price & Indicators
The closing range uses available history since Jul 24, 2026; less than a full year is stored.
Latest filings
60 Degrees reported clinical improvement and negative conventional PCR results in all five completed expanded access Babesiosis study patients; four were also negative on post-treatment NAT, while two additional patients remain on treatment, bringing enrollment to seven.
Read the 8-KQuarterly results
* Q4 derived as the full year minus Q1 to Q3.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| 16-ct box equivalents sold to U.S. pharmacies and dispensaries | 1,287 | the three months ended June 30, 2026 filing | +18.9% |
|
|
|||
| 3PL share of total net product sales of Arakoda | 92% | the three months ended June 30, 2026 filing | — |
| Biocelect sell-through boxes (Australia) | 497 | the three months ended June 30, 2026 filing | +25.5% |
|
|
|||
| Infuserve America share of total net product sales of Arakoda | 0% | the three months ended June 30, 2026 filing | — |
| Kodatef Australian distributor share of total net product sales of Arakoda | 8% | the three months ended June 30, 2026 filing | — |
| Scandinavian Biopharma sell-through boxes (Europe) | 103 | the three months ended June 30, 2026 filing | -6.4% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SXTPW
this stock
60 Degrees Pharmaceuticals, Inc.
|
$2.93M | — | +65.5% | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.20B | +14.9% | +46.2% | 30.2 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.7% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 25.0%
- Reported
- 1 of 12
- Top holder
- Kathmere Capital Manageme…
- Filed
- Oct 27, 2026
- This year
- 24
60 Degrees reported clinical improvement and negative conventional PCR results in all five completed expanded access Babesiosis study patients; four were also negative on post-treatment NAT, while two additional patients remain on treatment, bringing enrollment to seven.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SXTPW | +15.6% | -16.1% | — | +3.2% | — |
| SPY | -0.1% | 0.0% | +5.8% | +0.4% | +12.2% |
| vs SPY | +15.7% | -16.1% | — | +2.8% | — |